Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

First liquid solution for hypertension in cats
Semintra will be launched in a number of EU countries during September 2018.

Easy-to-give solution for pet owners and vets

The first liquid solution for feline hypertension has been launched by Boehringer Ingelheim.

In a press release, Boehringer Ingelheim said that Semintra 10 mg/ml Oral Solution ‘provides a new, well-accepted and easy-to-give liquid formulation, making management of feline hypertension easier for cat owners and veterinarians’.

“We are proud to continue to set new standards of care for cats to optimise their health and well-being through the veterinarian,” said Shawn Hooker, global head of strategic business unit pet vet at Boehringer Ingelheim.

“Early disease detection and early treatment are key to ensure cats live longer and happier lives. With Semintra we offer a pet owner-friendly, easy-to-give solution to help raise the quality of life of cats with hypertension while providing reliable long-term blood pressure control.”

The approval of Semintra as a veterinary medicine for the treatment of feline systemic hypertension follows marketing authorisation in the EU. It will be launched in a number of countries during September 2018.

Further information about Semintra can be found on the European Medicines Agency website.

Become a member or log in to add this story to your CPD history

Greyhound Board announces change to vaccination guidance

News Story 1
 The Greyhound Board of Great Britain has published new vaccination guidance, with all greyhounds registered from 1 January, 2027 required to have the L4 leptospirosis vaccination, rather than L2.

The change comes in response to the reduced availability of the 'L2' Leptospirosis vaccine across the UK, and aims to support best biosecurity practice across the racing greyhound population.

GBGB veterinary director Simon Gower, said "While rare, Leptospirosis is a serious infectious disease that can affect both dogs and humans, so it is vital that we offer our greyhounds the broadest possible protection.  

Click here for more...
News Shorts
Free webinar explores congenital heart disease in dogs

A free webinar is to provide veterinary professionals, dog breeders and pet owners an new insights into congenital heart disease.

Chris Linney, a cardiology specialist and Veterinary Cardiovascular Society (VSC) member, will present the webinar from 7.00pm to 8.30pm on Wednesday, 12 November.

Dr Linney will explore the types, causes and clinical presentation of congenital heart conditions. This will include diagnostic approaches, treatment pathways and emerging research opportunities.

The session is the third to be organised by The Kennel Club, with the VCS, following an introductory webinar and a talk on acquired heart disease. Dr Linney's webinar consists of a one-hour presentation, followed by a 30-minute question and answer session.

Dr Linney said: "This webinar will be an opportunity to deepen understanding - not just of the diseases themselves, but of how breeders, vets and owners can work together to support affected dogs and improve outcomes for future generations."

Click here to register for the webinar.